Department: Biochemistry and Molecular Biology

Research Unit: Instituto de Biotecnología y Salud (IDiBE)

Web page:

https://www.umh.es/contenido/Universidad/:persona_3704/datos_es.html

https://ibmc.umh.es/ferrer-montiel.asp

Research Fields:
-Peripheral Neuropathies

Representative Publications:

• Cabañero D, Carter EP, González-Cano R, Cobos EJ, Fernández-Carvajal A, Ferrer-Montiel A Cold receptor TRPM8 as a target for migraine-associated pain and affective comorbidities. J Headache Pain. 2025 Jun 23;26(1):146. doi: 10.1186/s10194-025-02082-4.
• Villalba-Riquelme E, de la Torre-Martínez R, Fernández-Carvajal A, Ferrer-Montiel A. Oxaliplatin reversibly and differentially affects electrogenic activity of small IB4(+) of male and female rat sensory neurons.  Biomed Pharmacother. 2025 Feb;183:117849. doi: 10.1016/j.biopha.2025.117849.
• Giorgi S, Lamberti A, Butrón L, Gross-Amat O, Alarcón-Alarcón D, Rodríguez-Cañas E, Fernández-Carvajal A,Ferrer-Montiel A. Compartmentalized primary cultures of dorsal root ganglion neurons to model peripheral pathophysiological conditions. Mol Pain. 2023 Jan-Dec;19:17448069231197102.
• Cabañero D, Villalba-Riquelme E, Fernández-Ballester G, Fernández-Carvajal A,Ferrer-Montiel A.  ThermoTRP channels in pain sexual dimorphism: new insights for drug intervention. Pharmacol Ther. 2022 Dec;240:108297.
• Alarcón-Alarcón D, Cabañero D, Andrés-López J, Nikolaeva-Koleva M, Giorgi S, Fernández-Ballester G, Fernández-Carvaja A, Ferrer-Montiel A. TRPM8 contributes to sex dimorphism by promoting recovery of normal sensitivity in a mouse model of chronic migraine. Commun. 2022, 13, 6304.
• Villalba-Riquelme E, de la Torre Martinez R, Fernández-Carvajal A, Ferrer-Montiel A. Paclitaxel in vitro reversibly sensitizes the excitability of IB4(-) and IB4(+) sensory neurons from male and female rats. J. Pharmacol. 2022, 179, 3693.
• Serafini M, Griglio A, Aprile S, Seiti F, Travelli C, Pattarino F, Grosa G, Sorba G, Genazzani AA, Gonzalez-Rodriguez S, Butron L, Devesa I, Fernandez-Carvajal A, Pirali T, Ferrer-Montiel A. Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders. J Med Chem. 2018 May 24;61(10):4436-4455. doi: 10.1021/acs.jmedchem.8b00109. Epub 2018 May 15.

Patents and Available Technologies:

1. Cristina Carreño, Berta Ponsati, Wim Van Den Nest, Jimena Fernández, María Camprubí Robles, Antonio Ferrer‑Montiel. Compositions for the treatment of pain and/or inflammation. WO2010/009892 A2. Parentide. Clinical development (Phase II). BCN Peptides.
2. Antonio Ferrer‑Montiel, Asia Fernández-Carvajal, Carlos Belmonte Martínez, Félix Viana, Juana Gallar, Pharmaceutical composition for the treatment of dry eye. WO2012/032209 A3. Clinical development dry eye (FDA approved 2025). Alcon.
3. Antonio Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño, Núria Almiñana, Raquel Delgado. Compounds which inhibit neuronal exocytosis. WO2013153196 (A1). Cosmeceutical development. L´OREAL/Lipotec.
4. Antonio Ferrer Montiel, Asia Fernández Carvajal, Isabel Devesa, Tracey Pirali, Armando Genazzani. TRPV1 modulator compounds. (EP3621950B1). Preclinical development for psoriatic pruritus; and cosmeceuticals for sensitive skin and hair care. AntalGenics SL.
5. Antonio Ferrer Montiel, Gregorio Fernández Ballester, Isabel Devesa. PCT/EP2024/087437 (2023). Phospholipase C inhibitor peptides and uses thereof.

Company agreements:

• Prospera Biotech
•  AntalGenics
•  Hawk Biosystems